22 results
CORRESP
VERV
Verve Therapeutics Inc
28 May 21
Correspondence with SEC
12:00am
Partners, L.P. and Wellington Biomedical Innovation Master Investors (Cayman) I L.P. GV informed the Company that there are no natural persons who
S-1
EX-10.1
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
, Janus Henderson Horizon Fund-Biotechnology Fund, and Janus Henderson Biotech Innovation Master Fund Limited.
1.19 “Key Employee” means any (i … “Wellington Biomed Fund” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
1.37 “Wellington Investors” means Investors
DRS
EX-10.1
VERV
Verve Therapeutics Inc
16 Apr 21
Draft registration statement
12:00am
, Janus Henderson Horizon Fund-Biotechnology Fund, and Janus Henderson Biotech Innovation Master Fund Limited.
1.19 “Key Employee” means any (i … “Wellington Biomed Fund” means Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
1.37 “Wellington Investors” means Investors
10-K
2021 FY
VERV
Verve Therapeutics Inc
14 Mar 22
Annual report
7:04am
Rights, the license is non-exclusive. The license follows the inclusive innovation strategy developed by Broad, MIT and Harvard.
Broad and Harvard also … ).
Under the Cas9 License Agreement, Broad and Harvard also retained rights to grant further licenses, through its inclusive innovation strategy, under
DEF 14A
o2rjp9t9satgcczhnjqn
29 Apr 22
Definitive proxy
7:01am
S-1
6nlpe 5imv4x5pkk8
28 May 21
IPO registration
4:04pm
424B4
x8zm1aevwczkbq
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
99tp4ah7yap4
14 Jun 21
IPO registration (amended)
6:15am
DRS
bn5bq
16 Apr 21
Draft registration statement
12:00am
DRS
EX-10.13
m7u1z0v
16 Apr 21
Draft registration statement
12:00am
S-1
EX-10.12
hiot8wwwjp8koygnlnk5
28 May 21
IPO registration
4:04pm